Fig. 3
From: Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer
Variations in PBL subsets during systemic therapy. (A-C). PBL subsets before and after treatment were available for (A) all BC patients and patients receiving (B) adjuvant therapy and (C) NAT. (D-E). PBL subsets before and after adjuvant therapy were available for (D) HR + HER2-, (E) HER2 + and (F) TN. Paired T test. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: NAT, neoadjuvant therapy; HR + HER2-, hormone receptor-positive/HER2-negative; HER2+, HER2-positive; TN, triple-negative